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in the A1cheive study. METHODS: The CORE Diabetes Model was used to make
long-term projections of clinical and cost outcomes associated with a 1% HbA1c
reduction based on A1chieve, a global, prospective, observational study of basal,
mealtime and biphasic insulin analogs in routine clinical practice. At baseline,
mean (SD) patient age was 60 (10) years, duration of diabetes 12 (5) years and HbA1c
9.2 (1.8)%. HbA1c was reduced by 1%-point from baseline in the active group rela-
tive to the control group. Life expectancy, complication rates and the cost of com-
plications were projected of a 35-year time horizon. Future costs and clinical out-
comes were discounted at 3% annually. Costs are presented in 2011 Algerian Dinar
(DZD), converted to Euros (EUR) at an exchange rate of DZD 1:EUR 0.096. RESULTS:
A 1% reduction in HbA1c was associated with improvements in both clinical and
economic outcomes. Undiscounted life expectancy was improved by 0.17 year with
a 1% improvement in HbA1c (6.58 versus 6.40 years). The cumulative incidence of
all diabetes related complications included in the analysis was lower in the 1%
HbA1c reduction group. Complication costs were DZD 9,669 (EUR 93) lower fol-
lowing HbA1c reduction (DZD 387,236 [EUR 3,717] versus DZD 396,905 [EUR
3810]). The most pronounced difference was in the cost of renal complications.
CONCLUSIONS:Glycemic control in A1chieve patients was generally suboptimal in
the Algerian setting. Improvements in glycemic control are likely to lead to sub-
stantial clinical and economic benefits due to reduced complication rates. Conse-
quently, the cost-effectiveness of intensifying treatment in these patients is wor-
thy of further analysis.
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OBJECTIVES: Diabetes represents a huge health care challenge for India. Estimates
suggest that there are over 61 million people living with diabetes in India (preva-
lence of 9.2% in adults), and diabetes caused approximately 983,000 deaths in 2011.
The aim of this study was to evaluate the benefits in long-term clinical and cost
outcomes associated with improving glycemic control in type 2 diabetes patients in
India. METHODS: Cohort characteristics were based on Indian patients in
A1chieve, a global, observational, prospective study of insulin analogs in daily
clinical practice. At baseline, patients had a mean (standard deviation) age of 51.8
(10.1) years, duration of diabetes of 6 (4.6) years and glycated hemoglobin (HbA1c) of
8.3% (1.4%). A published and validated model of type 2 diabetes (CORE Diabetes
Model) was used to make long-term projections of clinical outcomes and direct
costs (2011 Indian Rupees [INR], converted to Euros [EUR] at INR 0.015EUR 1).
Future costs and clinical benefits were discounted at 3% annually. RESULTS: Over
a 35-year time horizon, reducing HbA1c by 1% was projected to improve mean life
expectancy by 0.64 years (10.95 versus 11.59 years) and quality-adjusted life expec-
tancy by 0.53 QALYs (7.36 versus 7.89 QALYs). Benefits were driven by lower com-
plication rates with improved glycemic control. End-stage complications such as
myocardial infarction, end-stage renal disease, severe vision loss and lower limb
amputation were reduced by 4%, 46%, 33% and 3%, respectively (relative risk).
Direct costs were reduced by INR 33,443 (EUR 502) due to complications avoided
control (INR 256,101 [EUR 3,842] versus INR 222,659 [EUR 3,340]). CONCLUSIONS:
HbA1c levels are above guideline targets in India. Improving glycemic control is
likely to substantially lower the risk of complications, improve survival and reduce
complication costs. Cost-effectiveness analyses of interventions/management
programs designed to improve glycemic control are merited for the Indian setting.
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OBJECTIVES: Evaluate the cost-utility (CUA) of vildagliptin or sulphonylurea as add
on to metformin treatment for DMII patients for the Greek NHS METHODS: A
validated patient level simulation model was used based on UKPDS risk equations
(Clarke 2004) to estimate long run micro/macro-vascular complications and mor-
tality over a lifetime horizon. During each cycle a patient can experience different
complications: ischemic heart disease, myocardial infarction (MI), chronic heart
failure, renal failure, stroke, amputation, blindness in one eye. The outcomes as-
sessment criteria were Quality Adjusted Life Years (QALYs) and Life Years Gained
(LYG). Quality of life decrements were derived from literature. Discount rates of
3.5% were set for both costs and outcomes and univariate sensitive analysis was
conducted. Drug costs were based on Greek published list prices 2012, while com-
plication cost was obtained from International literature. RESULTS: The mean
number of QALYs per patient in the lifetime horizon was 6.24 in the
vildagliptin&metformin group and 6.16 in sulphonylurea&metformin group, re-
sulting in 0.08 QALYs in favor of vildagliptin&metformin group. Total costs per
patient were €7,848 in vildagliptin&metformin group and €7,572 for
sulphonylurea&metformin, resulting in €276 cost difference for the latter. The in-
cremental cost effectiveness ratio (ICER) for vildagliptin&metformin versus
sulfonylurea&metformin is estimated at €3.371 per QALY for a lifetime horizon.
Regarding the analysis on life years gained, vildagliptin&metformin group had on
average 8,01 LYG and sulphonylurea&metformin 7,93, leading to a difference of
0.08 years in favour of vildagliptin&metformin. ICER for vildagliptin&metformin
versus sulfonylurea&metformin is estimated at €3.424 per life years gained.
CONCLUSIONS: For the Greek NHS adding Vildagliptin to Metformin is projected to
be highly cost-effective for patients with type 2 diabetes who are not at HbA1C goal
on Metformin compared to adding SU to Metformin. The price difference of the two
comparators is bridged when complications’ cost is included in the analysis.
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OBJECTIVES: Achieving glycemic control forms the cornerstone of type 2 diabetes
management and is key in reducing diabetes-related complications. The aim of the
current analysis was to investigate the long-term clinical and economic benefits of
a 1% reduction in HbA1c in comparison with baseline levels for type 2 diabetes
patients enrolled in the A1chieve study (an international, prospective, observa-
tional study of insulin analogs within routine clinical practice) in the Mexican
setting. METHODS: The analysis was performed using the published and validated
CORE Diabetes Model, over a 35-year time horizon, with future costs and clinical
outcomes discounted at a rate of 3% per annum. At baseline, mean (SD) patient age
was 55(13) years, duration of diabetes 11(7.5) years and HbA1c 10.3(2.2)%. An HbA1c
reduction of 1% was applied in the active arm, after which it was assumed that
HbA1c remained constant. Captured costs included diabetes-related complications
and concomitant medications. Costs of antihyperglycemic treatment and adverse
events were not included. Costs are presented in 2011 Mexican Pesos (MXN) and
converted into Euros (EUR) (MXN 1 to EUR 0.058). RESULTS: A 1% reduction in
HbA1c was associated with increased life expectancy of 0.51 years (8.70 years ver-
sus 8.19 years) and reduced cumulative incidence of all modelled diabetes-related
complications. Total mean direct costs were MXN 41,875 (EUR 2,429) lower in pa-
tients with HbA1c of 9.3% versus those with HbA1c remaining at 10.3% (MXN
596,985 [EUR 34,625] versus MXN 638,860 [EUR 37,054]). This was driven by savings
from the reduced incidence of complications. CONCLUSIONS: Baseline glycemic
control in A1chieve type 2 diabetes patients in the Mexican setting was generally
poor. Even modest improvements in HbA1c are likely to lead to substantial clinical
and economic benefits, due to reduced complication rates. Consequently, the cost-
effectiveness of intensifying treatment is worthy of further analyses.
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OBJECTIVES: Vildagliptin has demonstrated efficacy on HbA1c comparable to
glimepiride after 2 years of add-on treatment to metformin with markedly reduced
hypoglycemic risk. The current analysis aims to assess the add-on of vildagliptin
versus generic sulphonylureas (SUs) to metformin using a cost-effectiveness anal-
ysis (CEA) framework from the Portuguese societal perspective. Whilst generic SUs
have a lower acquisition price, hypoglycemic events represent a significant eco-
nomic burden and therefore the CEA framework can contribute to better
decision-making. METHODS: The CEA utilized a patient level simulation model
building on the UKPDS risk equations to estimate micro/macro-vascular complica-
tions and mortality over a lifetime horizon. Clinical parameters in the current
model include: HbA1c levels, weight gain, systolic blood pressure, total cholesterol,
HDL and incidence of hypoglycemic events. Patient distribution on demographic
and clinical variables was based on Portuguese epidemiological data. The treat-
ment algorithm allows for treatment switch when: HbA1c goal is not met; drug
intolerance; poor compliance. Drug parameters and quality of life decrements were
derived from literature. Drug costs were based on Portuguese list prices, while the
unit cost of each complication was obtained from the Diagnosis Related Groups
tariff. RESULTS: On average, the add-on of vildagliptin was estimated to result in a
per patient gain of 0.11 QALY and an increase of €1,453 on total cost when com-
pared to the add-on of SU to metformin, resulting in an incremental cost-effective-
ness ratio of €12,794/QALY.CONCLUSIONS:Under the Portuguese societal perspec-
tive, adding vildagliptin is projected to be likely cost-effective for patients with type
2 diabetes who are not at HbA1c goal on metformin compared with adding generic
SUs.
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OBJECTIVES: Despite the growing incidence of diabetes, the occurrence of compli-
cations requiring hospitalization has stabilized in the last decade. Advances in
health care and improved access to innovative drugs may have led to these health
gains. We aimed to explore the relationship between patients’ access to newer oral
anti-diabetic drugs (OADs) and the number and costs of hospitalizations attribut-
able to diabetes. METHODS: For the period 2000-2009, we collected data on: 1) the
number of hospital admissions and their costs attributable to diabetes; 2) the num-
ber of patients treated for diabetes per year and health region, based on the OADs
consumption (treated prevalence); and 3) the evolution of the average vintage
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